FDA placed Chengdu KeCheng's APIs on import alert after it ignored FDA records requests.
What happened
FDA reviewed import records showing multiple shipments of API into the U.S. that named Chengdu KeCheng as the drug manufacturer. FDA sent electronic requests for records and information on July 18 and August 8, 2022, and a follow-up on March 9, 2023; the firm did not respond. On an October 24, 2022 call, the firm refused to give a full name or alternate email and said it was not shipping to the U.S. and would deregister, but FDA found continued API shipments to the U.S. as recently as January 2023.
What FDA found
The company did not respond to FDA's July 18, 2022 electronic request for records and information about its API manufacturing.
Section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)The company did not respond to FDA's second request on August 8, 2022 or the March 9, 2023 follow-up request.
Section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)FDA says refusing to permit access to or copying of required records is a prohibited act.
Section 301(e) of the FD&C Act, 21 U.S.C. 331(e)FDA has no indication of the level of quality assurance for drugs listed as manufactured at the facility because the firm did not respond.
What FDA wants
FDA asks the company to respond in writing within 15 working days, with the response identified by FEI 3014675751 and ATTN: Joel Hustedt. The company may provide information for FDA's consideration and/or request an FDA inspection.
Who should pay attention
- U.S. drugmakers that buy or use APIs from this firm
- supply chain and quality teams managing API suppliers
- companies relying on Chengdu KeCheng APIs in finished drug products
This is a summary. Read the original letter on fda.gov.